XNAS · Healthcare · Biotechnology
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 0.01 | -0.02 | -300.00% | $90.2M | ❌ Miss | -10.39% | -9.83% | — |
| 2026-02-26 | Q4 2025 | 0.01 | 0.01 | +0.00% | $112.0M | ➖ Inline | +5.71% | -12.65% | -29.63% |
| 2025-11-05 |
| Q3 2025 |
| 0.02 |
| 0.07 |
| +250.00% |
| $82.1M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 0.06 | 0.05 | -16.67% | $76.5M | ❌ Miss | +0.25% | +7.65% | +59.88% |
| 2025-02-26 | Q4 2024 | 0.03 | 0.08 | +166.67% | $76.8M | ✅ Beat | -4.39% | -5.85% | -8.04% |
| 2024-11-07 | Q3 2024 | 0.03 | 0.06 | +100.00% | $70.1M | ✅ Beat | -0.61% | -5.01% | -9.88% |
| 2024-08-07 | Q2 2024 | 0.01 | 0.05 | +400.00% | $72.4M | ✅ Beat | +3.59% | +3.59% | +18.36% |
| 2024-05-08 | Q1 2024 | 0.03 | 0.05 | +66.67% | $66.3M | ✅ Beat | -2.05% | +1.14% | +6.14% |
Showing last 8 quarters.